Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Sees Large Increase in Short Interest

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 13,600 shares, an increase of 56.3% from the October 15th total of 8,700 shares. Based on an average trading volume of 14,500 shares, the short-interest ratio is presently 0.9 days. Currently, 0.4% of the company’s stock are short sold.

Cryo-Cell International Stock Down 0.6 %

Shares of NYSEAMERICAN:CCEL opened at $8.43 on Friday. The firm has a market cap of $67.95 million, a P/E ratio of -7.95 and a beta of 0.43. Cryo-Cell International has a 1 year low of $3.67 and a 1 year high of $9.50.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.11. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%. The company had revenue of $8.07 million for the quarter.

Cryo-Cell International Announces Dividend

The company also recently announced a — dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, November 15th.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.